Original language | English |
---|---|
Pages (from-to) | 250-253 |
Number of pages | 4 |
Journal | International Journal of Cardiology |
Volume | 176 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 Sep |
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Evidence of pleiotropy by statins : Leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. / Liu, Ping Yen; Lee, Po Tseng; Chang, Wei Ting; Tai, Yun Ling; Chao, Ting Hsing; Lee, Cheng Han; Li, Yi Heng; Chen, Jyh Hong; Tsai, Liang Miin; Liao, James K.
In: International Journal of Cardiology, Vol. 176, No. 1, 09.2014, p. 250-253.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Evidence of pleiotropy by statins
T2 - Leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors
AU - Liu, Ping Yen
AU - Lee, Po Tseng
AU - Chang, Wei Ting
AU - Tai, Yun Ling
AU - Chao, Ting Hsing
AU - Lee, Cheng Han
AU - Li, Yi Heng
AU - Chen, Jyh Hong
AU - Tsai, Liang Miin
AU - Liao, James K.
N1 - Funding Information: Statin therapy prior to PCI is associated with overall improvement of cardiovascular outcome, mortality and peri-procedural myocardial injury after PCI in coronary artery disease (CAD) patients = 0.33). Multiple logistic regression analysis with forward stepwise selection showed that in addition to hypertension (Odds ratio (OR) 3.2), smoking behavior (OR 2.3) and diabetes mellitus (OR 2.1), baseline higher levels of ROCK activity (> 0.38) remained an independent predictor for CAD diagnosis (OR 2.8) (all P value 0.38, = 68) had 28 coronary events during the follow-up period, whereas patients with lower levels (≤ 0.38, = 70) had only 21 events (40.2% vs. 30%, P = 0.03) ( 0.9, = 62) had 27 coronary events during the follow-up period, whereas patients with lower levels (≤ 0.9, = 76) had only 22 events ( 0.38) or after PCI (> 0.9) and smoking were independent predictors of subsequent coronary events ( > 0.05). Interestingly, the outcome after PCI was not related to their baseline LDL level. However, the improvement in subsequent coronary events in patients with statin pretreatment was observed more significantly among patients with higher leukocyte ROCK activity (> 0.9) after PCI. These results suggest that leukocyte ROCK activity after PCI predicts long-term outcome in patients especially among those without pre-treatment of statins. Our study was limited due to retrospective design, smaller size of population and lack of other associated inflammatory marker inputs. This research was supported in part by the Headquarters of University Advancement at the National Cheng Kung University, sponsored by the [1–3] . In one meta-analysis report [4] , statin pre-treated was better than nothing in the odds ratio of future coronary event outcomes. Interestingly, the level of low-density lipoprotein (LDL) cholesterol did not correlate with their outcome after PCI. This result probably implied that statin therapy has vascular protection beyond LDL lowering effect, but not for the whole group. However, it remained unknown what factors or conditions can be more beneficial from statin pretreatment during the PCI procedure. Mechanisms had been proposed as the inhibition of Rho-associated coiled-coil containing protein kinase (ROCK) [5–7] and inflammation reaction including c reactive protein (CRP) [8] . These so-called “pleiotropic” or cholesterol-independent effects of statins have been associated with the mechanisms via improvement in flow-mediated vasodilation [9,10] , anti-inflammation [8,11] and also enhancement function of circulating vascular endothelial progenitor cells [12] . To test whether these important vascular biomarkers can predict those “high-risk” subgroup to be more beneficial to statin pretreatment strategy during PCI procedure, we conduct a clinical observational study based on the interplay of “pretreatment statin or not” and “the level of CRP or leukocyte ROCK activity” at baseline or after PCI, partially according our previous reports and methodologies [13–16] . We studied 138 patients who were documented as CAD with another 50 patients with normal coronary arteries who were compared as the control group. Patients' characteristics were presented in Table 1 . The prevalences of smoking behavior history, diabetes mellitus, hypertension, the levels of cholesterol as well as the baseline CRP and ROCK activity were all higher in the CAD group. There was no difference in the traditional cardiovascular risk factors, LDL-C levels and other inflammatory biomarkers when we divided the CAD group subjects into statin naïve or statin pretreated subgroups (Table S1). These data indicated that our study subgroups were well matched. The comparative procedural and angiographic characteristics of the subgroup defined by the pretreatment of statin or not were similar and presented in Table S1. The baseline ROCK activity did not correlate with baseline CRP levels (P Fig. 1 A. Both groups had similar leukocyte ROCK activity after diagnostic-only angiography. However, it increased immediately after coronary PCI. In contrast, though the levels of CRP and troponin-T did not increase immediately after PCI, these 2 biomarkers had the highest level at the 24-hour delay after PCI. In control group, there were no significant changes for all biomarkers. These data support the effect of plaque rupture caused by balloon or stent procedure that could trigger an immediate activation of ROCK pathway and also a later effect on both inflammation as well as myonecrosis damage on the heart. To compare the effect of statin on the observed biomarkers and PCI outcome, we further divided the CAD patients into statin pretreated or statin naïve subgroups before PCI. In addition, the serial changes of LDL-C before and after PCI procedure were shown without any difference. The statin naïve subgroup showed a significant elevation of leukocyte ROCK activity after PCI. Interestingly, the elevation of ROCK activity was less obvious among the statin pretreated subgroup. (Table S1 and Fig. 1 B). Because the statin naïve and pretreated subgroup subjects had similar baseline LDL-C and cholesterol levels, the serial changes of ROCK activity could thus be a “pleiotropic beneficial reaction” provided by statin pretreatment before PCI procedure. All patients received standard medical therapy following PCI and during follow-up. 236 patients after PCI were followed for a mean duration of 20.4 n n Fig. 2 A). This indicates that baseline ROCK activity itself is an outcome predictor after PCI. As for ROCK activity after PCI, those patients with higher levels of leukocyte ROCK activity after PCI (> n n Fig. 2 B). In addition, statin pretreatment affected the prognosis after a 2-year follow-up. Those patients with statin pretreatment were observed to have less subsequent cardiovascular or coronary events during follow-up ( Fig. 2 C). These data support the hypothesis that statin pretreatment can not only lower the baseline ROCK activity, but also ameliorate the responsive increase of ROCK activity during PCI procedure. Multivariate forward stepwise Cox proportional hazard analysis showed that higher levels of baseline ROCK activity (> Table 2 ). Finally, the protective effect of pretreated statin was not associated with the type, duration or dosage of statin nor the stent type used (data not shown, all P Ministry of Education and the National Science Council ( 95-2314-B-006-036-MY2 , 98-2314-B-006-047-MY3 and 101-2314-B-006-075-MY2 ), and the National Cheng Kung University Hospital, Tainan, Taiwan ( NCKUH-10204018 ) also the grant funded by the Ministry of Health and Welfare in Taiwan ( MOHW103-TDU-B-211-113002 ).
PY - 2014/9
Y1 - 2014/9
UR - http://www.scopus.com/inward/record.url?scp=84906317827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906317827&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2014.06.059
DO - 10.1016/j.ijcard.2014.06.059
M3 - Article
C2 - 25034804
AN - SCOPUS:84906317827
VL - 176
SP - 250
EP - 253
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 1
ER -